This is consistent with findings from a randomized controlled study by Ikonomidis et al. investigating the effect of insulin, glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), and their combination on vascular and cardiac function of persons with type 2 diabetes. Here, INS is linked to type 2 diabetes mellitus.